The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Skip to Page Content

Save the Date!

Pharmaceutical Strategy Conference 2013
September 23-25, 2013
Millennium Broadway Hotel - New York, NY
Add to Outlook

Building Sustainable Value Through New Relationships

As it searches for innovation to fuel sustainable growth, biopharma is dramatically reinventing its relationships across the board. Once entirely confident of its own strengths, the industry is displaying a new sensitivity to creative collaboration. Adaptive business models are selectively emerging. As parts of the heavily interdependent life sciences ecosystem undergo multi-year transformations, Big Pharma is acknowledging its responsibilities in propping up valuable, but capital-starved sources of long-term innovation. Getting closer to the patient is vital to the process. The result is novel cooperation among traditionally wary constituents: pharma, biotech, payers, providers and patients.

But can these arrangements, which aim to provide all parties with rewards and mitigate risk at various steps of the process deliver on value in a resource-constrained world? As pharma reaches further into emerging geographies, how does it balance growth in new markets with still-lucrative but shrinking opportunities at home? At this year's Pharmaceutical Strategic Alliances meeting we'll explore how companies can best use non-traditional partners to transform weak pipelines, jumpstart flagging revenues, and prove relevancy of their products to payers and health care providers.

Traditional alliances still have their place, though they represent a much smaller part of the strategic spectrum. Large drug companies are as apt to build relationships with venture capital partners, payers, data providers, academic centers, governments, and each other. These new relationships will generate ideas about industry's best paths forward – and create new pressures to find common ground with unfamiliar partners.

Top 10 reasons to attend Pharmaceutical Strategic Alliances

  • The Best Networking in the Business: The editorial team behind IN VIVO, STARTUP and "The Pink Sheet" bring you an unprecedented level of expertise and top analysis to our conference content.
  • Fast-Track Executive Training: There is no better way to quickly train your R&D/BD teams in two days than to hear healthy debates with key opinion leaders on how to move forward in the right direction.
  • Expand your Business and Your Career: Meet the key decisionmakers at numerous networking opportunities including the Welcome Reception and Gala Reception.
  • Excellent Case Studies: PSA is strategically packed with lessons learned, future biopharma trends, and actionable data to help improve your R&D/BD/Biotech business models.
  • Get Closer to your Patients: Hear novel externalization/ cooperation examples among traditionally wary constituents: venture capital partners, payors, data providers, academic centers, and governments.
  • Mitigate Risk: Understand the specifics driving biopharma deal-making to better calibrate ongoing negotiations.
  • Drive Value for your Drug: It’s a new commercial landscape so don’t fall behind the curve. Find out what the potential is for your products in a new marketplace of payer priorities. How will health care reform affect your launch?
  • Access Innovation to Fuel Sustainable Growth: Hear about the unprecedented scale of restructurings, adaptive business models, and how companies are tapping into new relationships and sources/cultures of innovation for driving their pipelines.
  • Unique Structure: PSA’s participants and agenda address the most timely and relevant issues for today’s industry. High-level strategy and details are well balanced in our panels.
  • Benchmark your R&D/BD Business Models against the Best, the Brightest and your Competitors: What are the key components for the new models? Get a clear picture of what it takes to win by benchmarking your strategies to the best in class. How are non-traditional partnerships supplanting the typical biotech-pharma alliance of years past?

Why do so many pharma companies send their leadership teams to PSA?

PSA offers case studies about today's top biopharma issues from CEOs, Senior R&D and Senior Business Development executives. Not only will they share lessons learned, and practical advice for sealing a deal, but these key opinion leaders will debate the issues that are top of mind -- from enhancing R&D productivity to doing more with less in Business Development. In addition, attendees will also have the chance to:

  • Meet potential partners and network in a relaxed setting
  • Understand externalization models and see how a company's approach meshes with potential partners
  • Benchmark the firm's dealmaking strategy against its competitors
  • Understand the specifics driving biopharma dealmaking to better calibrate ongoing negotiations

PSA is the only meeting to gather in one place the industry's top thinkers to explain solutions to the fundamental challenges facing biotech and pharma. In a limited period of time, it will equip dealmakers like you with the insights, information and practical advice you need to strike successful deals. This program will sell out so register early. Space is limited, so register today!

At this year's event you'll hear from, and be able to quiz, top industry executives and dealmakers about the following topics:

  • Building a Culture of Innovation: R&D Challenges of Large Organizations
  • The Solution-Development Model: New Strategies for Funding Development and Building Better Biotechs
  • Implementing Key Components for New R&D Models
  • Business Development: Do More with Less
  • Building Biotech Value: New Models for Modern Times
  • Tapping Into Reverse Innovation
  • Global Business Strategies for Accessing the Emerging Market
  • Strategies for Developing Global Biosimilars
  • Keying on the Provider System to Establish Drug/Dx Value
  • Maximizing Value in a New Commercial Landscape

Benchmark your corporate strategies against the best and the brightest.

The BIGGEST Names Send their Leadership Teams to PSA. And the hotel always sells out. Unprecedented networking.

  • Abbott
  • Allergan Inc.
  • AstraZeneca
  • Bayer Healthcare
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chugai Pharmaceutical Co.
  • Eli Lilly & Company
  • Genentech
  • Genzyme
  • GlaxoSmithKline
  • H. Lundbeck A/S
  • Hoffmann-La Roche
  • Merck and Company
  • Pfizer Inc.
  • Purdue Pharma LP
  • Sanofi
  • UCB Pharma SA

Attend the ONLY strategic-level conference that delivers 100% case studies by the most important people in the business.

Feedback About PSA

The moderators had done their homework with the respective panels. The format was much more informative and allowed a healthy debate on the various topics discussed."
- Sam Rasty, PhD Director, Corporate Development, Endo Pharmaceuticals
PSA has an unique structure, participants and venue for top Pharma executives, which address the most relevant issues to the industry today. A must-event for pharma executives who want to move forward in the right direction."
- Robert DeBenedetto, CEO, SFJ Pharmacueticals, Inc.
Well organized. Well attended. Moderators kept panel members focused on relevant topics; good balance between high-level and details. Great way to meet key decision makers."
- Peter Kolchinsky, Managing Partner, RA Capital
Very good information presented during the the panel sessions. Excellent participants with a clear understanding and influence of future pharma/biotech trends."
- Joe Panegasser, Director, Alliance Management PPD Inc.

Registration Assistance


For more information on PSA 2012, or to register over the phone, please contact:

Denise Struble
Phone: (908) 547-2067